NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated leader in pharmaceutical innovation, with a profound commitment to advancing cancer treatment. Our cutting-edge research focuses on developing novel therapeutic strategies, including the creation of sophisticated SN38-glucose conjugates, specifically designed to target and combat various forms of cancer, notably colorectal cancer.

The core of our innovation lies in understanding the unique metabolic landscape of cancer cells. Cancer cells are characterized by their accelerated metabolism, particularly their increased reliance on glucose for energy and growth. This heightened glucose uptake is often facilitated by the overexpression of glucose transporters on the cell surface. NINGBO INNO PHARMCHEM CO.,LTD. is effectively harnessing this phenomenon through the development of SN38-glucose conjugates. This strategy is a testament to the power of glucose transporter targeted drug delivery, enabling the potent cytotoxic agent SN38 to be selectively delivered to cancer cells.

Our research team has successfully synthesized and rigorously tested a series of these SN38-glucose conjugates. A standout compound, designated as 5b, has demonstrated exceptional efficacy in preclinical studies. It exhibits potent antiproliferative activity against colorectal cancer cell lines and has shown significant success in inhibiting tumor growth in vivo. The mechanism of action involves not only the targeted delivery of SN38 but also its effectiveness in inducing cancer cell apoptosis and impeding their migratory capabilities. These attributes highlight the potential of our novel SN38 glucose conjugates targeting cancer cells.

The quest for superior anticancer agents for CRC treatment is ongoing, and our work with SN38-glucose conjugates marks a significant advancement in this field. NINGBO INNO PHARMCHEM CO.,LTD. is committed to breakthroughs in novel anticancer compound synthesis, aiming to deliver therapies that are both highly effective and significantly safer for patients. Our focus on selective chemotherapy for colorectal cancer ensures that we prioritize treatments offering enhanced therapeutic benefits with minimized side effects.

As a trusted supplier of pharmaceutical intermediates and active pharmaceutical ingredients, NINGBO INNO PHARMCHEM CO.,LTD. is equipped to support global research and development efforts. Our contributions to preclinical oncology drug development are driven by a mission to make a meaningful difference in the lives of cancer patients. We actively seek partnerships to further advance the field of oncology.

We invite you to collaborate with NINGBO INNO PHARMCHEM CO.,LTD. to explore the future of targeted cancer therapies. Together, we can advance the development of innovative treatments and improve patient outcomes for colorectal cancer and other oncological conditions.